Frequently Asked Questions – FAQ

Stem cells can renew themselves and produce more specialized cells through differentiation. Their range of possible cell types depends on the population. Blood-forming stem cells produce blood and immune cells; this does not establish that they rebuild lung or heart tissue. Research in regenerative medicine must be distinguished from demonstrated treatment benefit. Our pages on COPD, IPF and heart failure address different conditions and should not be read as proof of blood-cell conversion into those organs. See the introduction to stem cells for background.

Autologous means cells from the same person; allogeneic means cells from a donor. These terms describe donor relationship, not a universal ranking of effectiveness. Tissue sources, including cord blood, placental tissues and dental pulp, contain different cell populations. Selection depends on the specific intervention and condition. Donor-derived mesenchymal stromal cells should not be assumed to evade every immune response, and a younger donor alone does not establish superior clinical results.

Cell source and the intended intervention should be described separately. Adult tissue stem cells include populations in bone marrow and other tissues. Blood-forming cells may be collected from marrow, peripheral blood or umbilical cord blood. Cord blood and cord tissue are different materials. Marrow collection may involve the iliac crest; G-CSF mobilization is used in some collection protocols and is not a required step for every marrow collection. Mesenchymal stromal cell preparation is a separate topic. Embryonic stem cells are another category; the center does not offer embryonic stem cell therapies. Ask the clinical team to identify the actual source and product proposed for your case.

Both can provide blood-forming cells, but their collection, matching, available cell dose and recovery characteristics differ. Cord blood is collected after birth and stored; marrow is collected from a donor. Neither source is universally preferable. A transplant team considers the diagnosis, patient size, donor availability and the particular graft. Cord blood is not guaranteed to be infection-free or suitable for every recipient. Donor screening, testing and matching remain necessary. See the cord blood guide for background.

Human leukocyte antigens, or HLA, are inherited markers used when assessing donor-recipient compatibility for blood-forming cell transplantation. Matching requirements depend on the transplant approach and source. There is no single rule that every transplant requires only three of six markers to match. Compatibility testing supports donor selection; it does not eliminate all transplant risks. The hematopoietic transplant team determines the relevant tests and matching criteria.

Graft-versus-host disease, or GVHD, occurs when donor immune cells attack the recipient’s tissues after an allogeneic transplant. This is different from the recipient rejecting the graft. It can affect multiple organs, may be acute or chronic, and can be serious. Risk and prevention depend on the transplant and clinical circumstances. The distinction between autologous and donor transplants is important; it should not be used to describe any cell procedure as risk-free.

Viability is the proportion of cells judged alive by a specified test at a specified time. Potency concerns a preparation’s relevant biological activity and depends on the product and assay. A viable-cell count is not the same as demonstrated effectiveness in a patient. Ask when testing occurred, whether the sample was assessed after thawing when applicable, what the assay measures, and which acceptance criteria were used. The term potency should not be used as a general promise of tissue repair.

Quality depends on the defined product, collection, processing, testing, storage and handling procedures. Faster processing or a higher cell count alone does not prove greater effectiveness. A closed processing system does not eliminate every contamination risk. Ask for the product-specific controls, test results, traceability and handling information rather than a blanket assurance of safety or success. Information about the center is available on its institutional page.

Cell banking means processing and storing a defined cell preparation for possible future use. The storage agreement should identify the material, testing, storage conditions, charges and release arrangements. Banking a sample does not guarantee that it will be suitable or that a treatment using it will become available. Ask the bank which uses are established for that material and what happens if the sample cannot be released.

There is no single guaranteed storage lifetime for every cell product. Suitability depends on the material, validated processing and storage conditions, monitoring and the tests required when the sample is released. A stated contract term is different from evidence that cells remain usable for a particular treatment. Ask the bank for its documented storage term, supporting data and release criteria. Obtain the current written terms for any proposed storage service.

Ask for the identity of the preparation, relevant cell counts, viability, contamination testing and the applicable release criteria. Flow cytometry may characterize particular cell populations; a CD34 count relates to blood-forming progenitor cells and is not a universal measure of every MSC product. A laboratory report should identify what was measured and when. Passing a laboratory test does not by itself establish clinical benefit.

Cryopreservation requires a validated storage method, defined temperature limits, sample identification, monitoring, backup arrangements and documented handling. Storage conditions differ between systems, so a single temperature should not be presented as suitable for every product. Ask the bank how samples are traced, how excursions are handled and how release and transport are controlled. For details about a proposed service, contact the team for the current written information.